- Home
- MBOT vs HCWB Comparison
MBOT vs HCWB Comparison
Compare MBOT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | HCWB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.7M | 3.7M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBOT | HCWB |
|---|---|---|
| Price | $2.40 | $0.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.50 | ★ $35.00 |
| AVG Volume (30 Days) | 1.4M | ★ 20.7M |
| Earning Date | 03-26-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,887.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $120.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.22 |
| 52 Week High | $4.62 | $17.80 |
Technical Indicators
Market Signals| Indicator | MBOT | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 33.10 |
| Support Level | $2.34 | N/A |
| Resistance Level | $2.60 | $0.78 |
| Average True Range (ATR) | 0.15 | 0.14 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 26.05 | 0.96 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.